PDL Biopharma Inc’s (NASDAQ:PDLI) Sentiment is 0.8

December 14, 2017 - By Adrian Mccoy

 PDL Biopharma Inc's (NASDAQ:PDLI) Sentiment is 0.8

Sentiment for PDL Biopharma Inc (NASDAQ:PDLI)

PDL Biopharma Inc (NASDAQ:PDLI) institutional sentiment decreased to 0.8 in Q2 2017. Its down -0.06, from 0.86 in 2017Q1. The ratio is negative, as 57 active investment managers increased or opened new positions, while 71 reduced and sold their stakes in PDL Biopharma Inc. The active investment managers in our partner’s database now have: 123.93 million shares, down from 126.21 million shares in 2017Q1. Also, the number of active investment managers holding PDL Biopharma Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 58 Increased: 36 New Position: 21.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $442.95 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It has a 5.83 P/E ratio. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

The stock decreased 2.71% or $0.08 during the last trading session, reaching $2.87. About 607,692 shares traded. PDL BioPharma, Inc. (NASDAQ:PDLI) has declined 26.03% since December 14, 2016 and is downtrending. It has underperformed by 42.73% the S&P500.

Analysts await PDL BioPharma, Inc. (NASDAQ:PDLI) to report earnings on March, 7. PDLI’s profit will be $16.98M for 6.52 P/E if the $0.11 EPS becomes a reality. After $0.14 actual EPS reported by PDL BioPharma, Inc. for the previous quarter, Wall Street now forecasts -21.43 % negative EPS growth.

Kestrel Investment Management Corp holds 1.59% of its portfolio in PDL BioPharma, Inc. for 1.74 million shares. Nine Chapters Capital Management Llc owns 37,400 shares or 0.87% of their US portfolio. Moreover, Tfs Capital Llc has 0.32% invested in the company for 333,728 shares. The United Kingdom-based Gsa Capital Partners Llp has invested 0.13% in the stock. Seizert Capital Partners Llc, a Michigan-based fund reported 1.26 million shares.#img1#

PDL BioPharma, Inc. (NASDAQ:PDLI) Ratings Coverage

Ratings analysis reveals 50% of PDL BioPharma’s analysts are positive. Out of 4 Wall Street analysts rating PDL BioPharma, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $3.0 while the high is $7. The stock’s average target of $3.75 is 30.66% above today’s ($2.87) share price. PDLI was included in 9 notes of analysts from October 16, 2015. The firm has “Sector Perform” rating given on Tuesday, February 23 by RBC Capital Markets. The company was maintained on Friday, November 3 by Piper Jaffray. Cowen & Co maintained PDL BioPharma, Inc. (NASDAQ:PDLI) on Thursday, October 26 with “Hold” rating. The rating was maintained by RBC Capital Markets with “Sector Perform” on Tuesday, February 2. PiperJaffray maintained the stock with “Overweight” rating in Thursday, December 22 report. RBC Capital Markets maintained the shares of PDLI in report on Thursday, November 5 with “Sector Perform” rating. RBC Capital Markets maintained PDL BioPharma, Inc. (NASDAQ:PDLI) rating on Friday, October 16. RBC Capital Markets has “Sector Perform” rating and $7 target. The company was maintained on Friday, August 4 by Cowen & Co.

Another recent and important PDL BioPharma, Inc. (NASDAQ:PDLI) news was published by Seekingalpha.com which published an article titled: “FDA OKs expanded use for Noden’s hypertension med Tekturna” on November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.